Successful rapid desensitization for cetuximab-induced anaphylaxis
Allergy, Asthma & Respiratory Disease
;
: 294-296, 2015.
Artículo
en Coreano
| WPRIM
| ID: wpr-83768
ABSTRACT
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias del Colon Sigmoide
/
United States Food and Drug Administration
/
Inmunoglobulinas
/
Desensibilización Inmunológica
/
Cetuximab
/
Hipersensibilidad
/
Anafilaxia
Tipo de estudio:
Guía de Práctica Clínica
Límite:
Anciano
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
Allergy, Asthma & Respiratory Disease
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS